Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833

Journal of Clinical Oncology

Volumn 19, Issue 3, 2001, Pages 832-842

  Chico, I ^a   Kang, M H ^a   Bergan, R ^a   Abraham, J ^a   Bakke, S ^a   Meadows, B ^a   Rutt, A ^a   Robey, R ^a   Choyke, P ^a   Merino, M ^a   Goldspiel, B ^a   Smith, T ^a   Steinberg, S ^a   Figg, W D ^a   Fojo, T ^a   Bates, S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VALSPODAR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ATAXIA; BONE MARROW SUPPRESSION; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DISTRIBUTION; HUMAN; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MULTIDRUG RESISTANCE; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STEADY STATE; STOMATITIS;

EID: 0035253714     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.3.832     Document Type: Article

References (32)

1. Multidrug resistance: Molecular mechanisms and clinical relevance
2. Overcoming of vincristine resistance in P 388 leukemia in vivo and in vitro through enhancing cytotoxicity of vincristine and vinblastine by verapamil
3. Chemosensitizers in tumor therapy: New compounds promise better efficacy
4. SDZ PSC 833, a non-immunosuppressive cyclosporine: Its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia
5. Future perspectives for the development of P-glycoprotein modulators
6. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions
7. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
8. P-glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines
9. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia
10. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma: A phase I study
11. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors
12. R) in doxorubicin or mitoxantrone refractory breast cancer
13. A phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance
14. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: A Cancer and Leukemia Group B study
15. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer
16. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses Multidrug resistance conferred by overexpression of both MDR 1 and MRP
17. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (valspodar)
18. PSC833: Initial clinical results in refractory ovarian cancer patients
19. Phase I study of paclitaxel in combination with a multidrug resistance modulator: PSC 833 (valspodar) in refractory malignancies
20. Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: Implications for coadministration
21. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
22. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient mice
23. The erythromycin breath test predicts the clearance of midazolam
24. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation
25. Drug metabolism by cytochromes P450 in the liver and small bowel
26. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918
27. Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833
28. P-glycoprotein expression and function in circulating blood cells from normal volunteers
29. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype
30. Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease
31. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic cancer
32. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer: The European Cancer Centre